The stock is up 23% in early trading on more than 5400 trades and 3.4 million in volume. Shares are trading around .31
AcelRx Pharmaceuticals: Finally, Plan B
- On May 16, 2022 ACRX announced the company was in active discussions with potential commercial partners to take on DSUVIA.
- In such case, ACRX would essentially give up the main asset on which its story was built on so far.
- The company has acquired further assets over the past twelve months, ensuring a basis for further revenue.
- Without knowledge of the DSUVIA deal it is hard to assess the prospect, so I retain a Neutral rating with a tilt to Buy, as I believe in some short-term upside potential.
